- Home
- ZNB vs CANF Comparison
ZNB vs CANF Comparison
Compare ZNB & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNB | CANF |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | China | Israel |
| Employees | 14 | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.7M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | ZNB | CANF |
|---|---|---|
| Price | $1.75 | $3.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 110.8K | 22.7K |
| Earning Date | 11-12-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.17 |
| 52 Week High | $9.78 | $10.40 |
Technical Indicators
Market Signals| Indicator | ZNB | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 47.62 | 45.66 |
| Support Level | $1.41 | $2.93 |
| Resistance Level | $2.08 | $4.74 |
| Average True Range (ATR) | 0.24 | 0.17 |
| MACD | -0.08 | 0.05 |
| Stochastic Oscillator | 31.65 | 76.47 |
Price Performance
Historical ComparisonAbout ZNB Zeta Network Group Class A Ordinary Shares
Zeta Network Group is an entertainment technology company with a network that focuses on the application of technology and artificial intelligence in the entertainment industry. It provides online entertainment performances and online education through its wholly-owned subsidiaries Color Metaverse and CACM. The curriculum developed by the company includes music, sports, animation, painting and calligraphy, film and television, and life skills, covering various aspects of entertainment, sports, and culture.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.